Drug profile · INN
isoproterenol hydrochloride
ISOPROTERENOL HYDROCHLORIDE
isoproterenol hydrochloride (ISOPROTERENOL HYDROCHLORIDE) is a adrenergic receptor beta agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: rectal, sublingual. Current US regulatory status: approved.
Drug details — isoproterenol hydrochloride
- US status
- approved
- Class
- —
- Route
- RECTAL, SUBLINGUAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
isoproterenol hydrochloride (ISOPROTERENOL HYDROCHLORIDE) is a adrenergic receptor beta agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: rectal, sublingual. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor beta agonist
Primary target: Adrenergic receptor beta
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is isoproterenol hydrochloride?
isoproterenol hydrochloride (ISOPROTERENOL HYDROCHLORIDE) is a adrenergic receptor beta agonist. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: rectal, sublingual. Current US regulatory status: approved.
What is the brand name for isoproterenol hydrochloride?
ISOPROTERENOL HYDROCHLORIDE is a marketed brand name for isoproterenol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of isoproterenol hydrochloride?
isoproterenol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.